

Updated: 08/2020 DMMA Approved: 08/2020

## Request for Prior Authorization for Diacomit (Stiripentol) Website Form – <u>www.highmarkhealthoptions.com</u> Submit request via: Fax - 1-855-476-4158

All requests for Diacomit (Stiripentol) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

## Diacomit (Stiripentol) Prior Authorization Criteria:

For all requests for Diacomit (stiripentol) all of the following criteria must be met:

- Members stabilized on the medication will not be required to try and fail formulary alternatives.
- Member must be 2 years of age or older
- Treatment is prescribed by, or in consultation with, a neurologist
- Medication must be used as adjunctive therapy with valproic acid and clobazam (prior authorization required)
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines

Coverage may be provided with a <u>diagnosis</u> of Dravet syndrome and the following criteria is met:

- Documentation that the member's seizures are uncontrolled while on stable antiepileptic drug therapy
- Must provide documentation showing the member has tried and failed (which will be verified via pharmacy claims if available) or had an intolerance or contraindication to Topiramate
- Initial Duration of Approval: 6 months
- Reauthorization criteria:
  - Must provide documentation showing treatment with Diacomit has provided improvement in the member's condition.
- **Reauthorization duration of approval**: 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.



Updated: 08/2020 DMMA Approved: 08/2020

DIACOMIT (STIRIPENTOL) PRIOR AUTHORIZATION FORM					
Please complete and fax all requested information below including any progress notes, laboratory test results, or chart					
documentation as applicable to Highmark Health Options Pharmacy Services. FAX: (855) 476-4158					
If needed, you may call to speak to a Pharmacy Services Representative.					
PHONE: (844) 325-6251 Monday through Friday 8:30am to 5:00pm					
PROVIDER INFORMATION					
Requesting Provider:		NPI:			
Provider Specialty: Office Address:		Office Ph	ce Contact:		
Office Address:	•	Office Fax			
MEMBER INFORMATION					
Member Name:	DOB:				
Health Options ID:	Member	weight:	pounds or	_kg	
REQUESTED DRUG INFORMATION					
Medication:	Strength:				
Frequency:	Duratio	Duration:			
Is the member currently receiving requested medication? Yes No Date Medication Initiated:					
Is this medication being used for a chronic or long-term condition for which the medication may be necessary for the life of					
the patient? Yes No					
Billing Information					
This medication will be billed: at a pharmacy <b>OR</b>					
medically (if medically please provide a JCODE:					
Place of Service: Hospital Provider's office Member's home Other					
Place of Service Information   Name: NPI:					
Name: Address:					
Address.		Phone:			
MEDICAL HISTORY (Complete for ALL requests)					
Diagnosis:					
Is the member's seizures currently uncontrolled on current therapy? Yes No					
CURRENT or PREVIOUS THERAPY					
Medication Name Strength/ Frequency	Dates of		Status (Discontinued & Why/Curr	ent)	
Serengen Frequency	Dutto of	Incrupy	Status (Discontinued & Why, Suit		
REAUTHO	)RIZATI(	DN			
Has the member experienced a significant improvement with the	reatment?	Yes [	No		
Please describe:					
SUPPORTING INFORMATION or CLINICAL RATIONALE					
Prescribing Provider Signature			Date		